We are very happy that CymaBay Therapeutics chose to present the convincing data from their study in the NIF mouse. They nicely show that Seladelpar, which is a substance in clinical studies, reduces fibrosis in the NIF mouse in both liver and kidney. You will find the PDF of the poster “Seladelpar reduces established liver and renal fibrosis in the non-obese diabetic inflammation and fibrosis (NIF) mouse model” by clicking here.